BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Laboratorios Farmaceuticos Rovi SA

Open

BrancheGesundheitswesen

51.05 -0.2

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

50.85

Max

51.25

Schlüsselkennzahlen

By Trading Economics

Einkommen

-57M

32M

Verkäufe

199M

434M

KGV

Branchendurchschnitt

18.367

57.333

EPS

0.457

Dividendenrendite

2.25

Gewinnspanne

7.411

Angestellte

2,197

EBITDA

40M

138M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+52.15% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.25%

2.63%

Nächstes Ergebnis

7. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-896M

2.5B

Vorheriger Eröffnungskurs

51.25

Vorheriger Schlusskurs

51.05

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Alphabet, Intel, AppFolio

24. Apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. Apr. 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. Apr. 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. Apr. 2025, 23:13 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. Apr. 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. Apr. 2025, 22:51 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. Apr. 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. Apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. Apr. 2025, 22:38 UTC

Market Talk
Ergebnisse

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. Apr. 2025, 22:24 UTC

Market Talk
Ergebnisse

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. Apr. 2025, 22:23 UTC

Ergebnisse

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. Apr. 2025, 22:09 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. Apr. 2025, 22:00 UTC

Market Talk
Ergebnisse

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. Apr. 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. Apr. 2025, 21:23 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. Apr. 2025, 21:04 UTC

Ergebnisse

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. Apr. 2025, 21:02 UTC

Ergebnisse

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer-Vergleich

Kursveränderung

Laboratorios Farmaceuticos Rovi SA Prognose

Kursziel

By TipRanks

52.15% Vorteil

12-Monats-Prognose

Durchschnitt 77.75 EUR  52.15%

Hoch 90 EUR

Tief 65.5 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Laboratorios Farmaceuticos Rovi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

49.58 / N/AUnterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.